Phase I clinical trial - Phases précoces tumeurs solides

DRIIV-1 (OX2016 -203-01)
Phases précoces tumeurs solides
Ouvert depuis le: 07.22.2019
Site: Paris
Public cible
Adulte
An open-label, dose-escalation phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors.
Description de l'essai

This will be a phase I clinical trial escalating dose testing AsiDNA administered intravenously (iv) as monotherapy. The aim of the study is to assess the safety, pharmacokinetics and pharmacodynamics and preliminary efficacy of AsiDNA in patients with solid tumors.